FDA Finalizes Labeling Changes Rule

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

FDA has finalized a regulation regarding changes to an approved new drug application (NDA), biologics license application (BLA), or medical device premarket approval applicatin (PMA).

Rockville, MD (Aug. 22)-FDA has finalized a regulation regarding changes to an approved new drug application (NDA), biologics license application (BLA), or medical device premarket approval application (PMA). The regulation clarifies a January 2008 FDA proposal indicating when manufacturers may submit a changes being effective (CBE) supplement to amend the labeling for an approved product that would “reflect newly acquired information and to add or strengthen a contraindication, warning, precaution, or adverse reaction.”

The final amended CBE regulation further clarifies the definition of “newly acquired information” to be “data, whether derived from new clinical studies, reports of adverse events, or new analyses of previously submitted data” must be of a “different type or greater severity or frequency than previously included in submissions to FDA.”

The January 2008 proposal suggested the “newly acquired information” referred only to data derived from reports of adverse events.

The final regulation will take effect September 22, 2008.

A complete description of the proposed change was published in the Federal Register.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes